• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳入 6 个易于获得的参数的列线图以鉴别肝内胆管细胞癌和肝细胞癌。

A nomogram incorporating six easily obtained parameters to discriminate intrahepatic cholangiocarcinoma and hepatocellular carcinoma.

机构信息

Department of Laboratory Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, 200438, China.

Department of Surgery, University of Michigan Medical School, Ann Arbor, 48109, Michigan.

出版信息

Cancer Med. 2018 Mar;7(3):646-654. doi: 10.1002/cam4.1341. Epub 2018 Feb 23.

DOI:10.1002/cam4.1341
PMID:29473340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5852370/
Abstract

Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are the most prevalent histologic types of primary liver cancer (PLC). Although ICC and HCC share similar risk factors and clinical manifestations, ICC usually bears poorer prognosis than HCC. Confidently discriminating ICC and HCC before surgery is beneficial to both treatment and prognosis. Given the lack of effective differential diagnosis biomarkers and methods, construction of models based on available clinicopathological characteristics is in need. Nomograms present a simple and efficient way to make a discrimination. A total of 2894 patients who underwent surgery for PLC were collected. Of these, 1614 patients formed the training cohort for nomogram construction, and thereafter, 1280 patients formed the validation cohort to confirm the model's performance. Histopathologically confirmed ICC was diagnosed in 401 (24.8%) and 296 (23.1%) patients in these two cohorts, respectively. A nomogram integrating six easily obtained variables (Gender, Hepatitis B surface antigen, Aspartate aminotransferase, Alpha-fetoprotein, Carcinoembryonic antigen, Carbohydrate antigen 19-9) is proposed in accordance with Akaike's Information Criterion (AIC). A score of 15 was determined as the cut-off value, and the corresponding discrimination efficacy was sufficient. Additionally, patients who scored higher than 15 suffered poorer prognosis than those with lower scores, regardless of the subtype of PLC. A nomogram for clinical discrimination of ICC and HCC has been established, where a higher score indicates ICC and poor prognosis. Further application of this nomogram in multicenter investigations may confirm the practicality of this tool for future clinical use.

摘要

肝内胆管细胞癌 (ICC) 和肝细胞癌 (HCC) 是原发性肝癌 (PLC) 最常见的组织学类型。虽然 ICC 和 HCC 有相似的危险因素和临床表现,但 ICC 的预后通常比 HCC 差。在手术前准确地区分 ICC 和 HCC 有利于治疗和预后。鉴于缺乏有效的鉴别诊断生物标志物和方法,基于现有临床病理特征构建模型是必要的。列线图提供了一种简单有效的鉴别方法。共收集了 2894 例接受 PLC 手术的患者。其中,1614 例患者形成了列线图构建的训练队列,随后 1280 例患者形成了验证队列,以验证模型的性能。在这两个队列中,组织病理学证实的 ICC 分别诊断为 401 例 (24.8%) 和 296 例 (23.1%)。根据赤池信息量准则 (AIC),提出了一个整合六个易于获得的变量(性别、乙型肝炎表面抗原、天门冬氨酸氨基转移酶、甲胎蛋白、癌胚抗原、糖类抗原 19-9)的列线图。将 15 分作为截断值,对应的判别效能足够。此外,评分高于 15 的患者无论 PLC 亚型如何,预后均比评分较低的患者差。已经建立了用于 ICC 和 HCC 临床鉴别诊断的列线图,其中较高的分数表示 ICC 和较差的预后。在多中心研究中进一步应用该列线图可以证实该工具在未来临床应用中的实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70dd/5852370/eaf757998dad/CAM4-7-646-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70dd/5852370/207a432911e8/CAM4-7-646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70dd/5852370/eaf757998dad/CAM4-7-646-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70dd/5852370/207a432911e8/CAM4-7-646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/70dd/5852370/eaf757998dad/CAM4-7-646-g002.jpg

相似文献

1
A nomogram incorporating six easily obtained parameters to discriminate intrahepatic cholangiocarcinoma and hepatocellular carcinoma.纳入 6 个易于获得的参数的列线图以鉴别肝内胆管细胞癌和肝细胞癌。
Cancer Med. 2018 Mar;7(3):646-654. doi: 10.1002/cam4.1341. Epub 2018 Feb 23.
2
Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.基于炎症指标的列线图用于鉴别肝内胆管细胞癌与肝细胞癌。
Cancer Med. 2020 Feb;9(4):1451-1461. doi: 10.1002/cam4.2823. Epub 2020 Jan 5.
3
[A comparative study of intrahepatic cholangiocarcinoma and hepatocellular carcinoma with reference to clinical features and prognosis].[肝内胆管癌与肝细胞癌的临床特征及预后比较研究]
Zhonghua Gan Zang Bing Za Zhi. 2019 Jul 20;27(7):511-515. doi: 10.3760/cma.j.issn.1007-3418.2019.07.007.
4
Serum N-glycan fingerprint helps to discriminate intrahepatic cholangiocarcinoma from hepatocellular carcinoma.血清 N-糖指纹图谱有助于鉴别肝内胆管细胞癌和肝细胞癌。
Electrophoresis. 2021 Jun;42(11):1187-1195. doi: 10.1002/elps.202000392. Epub 2021 Mar 1.
5
The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.肝细胞癌合并胆管细胞癌、肝细胞癌和肝内胆管细胞癌术后的临床特征和预后因素:倾向评分匹配分析。
Int J Med Sci. 2021 Jan 1;18(1):187-198. doi: 10.7150/ijms.50883. eCollection 2021.
6
Utility of mean platelet volume in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.平均血小板体积在鉴别肝内胆管细胞癌与肝细胞癌中的作用。
BMC Gastroenterol. 2022 Jun 6;22(1):288. doi: 10.1186/s12876-022-02348-0.
7
Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study.肝胆细胞癌的临床病理特征、治疗、生存和预后因素:基于 SEER 数据库的列线图开发及多中心研究验证。
Eur J Surg Oncol. 2022 Jul;48(7):1559-1566. doi: 10.1016/j.ejso.2022.01.023. Epub 2022 Jan 31.
8
Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.高危患者肝内胆管细胞癌与肝细胞癌的鉴别诊断:应用超声造影的预测模型。
World J Gastroenterol. 2018 Sep 7;24(33):3786-3798. doi: 10.3748/wjg.v24.i33.3786.
9
Intrahepatic cholangiocarcinoma diagnosed preoperatively as hepatocellular carcinoma.术前诊断为肝细胞癌的肝内胆管癌。
J Surg Oncol. 2004 Aug 1;87(2):80-3; discussion 83-4. doi: 10.1002/jso.20091.
10
Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.甲胎蛋白-L3血清学阳性的肝内胆管癌患者以及肝细胞癌合并胆管癌患者的临床病理特征
J Gastroenterol Hepatol. 2006 May;21(5):869-73. doi: 10.1111/j.1440-1746.2006.04257.x.

引用本文的文献

1
Establishment and validation of a nomogram containing cytokeratin fragment antigen 21-1 for the differential diagnosis of intrahepatic cholangiocarcinoma and hepatocellular carcinoma.用于肝内胆管癌和肝细胞癌鉴别诊断的包含细胞角蛋白片段抗原21-1的列线图的建立与验证
Front Oncol. 2024 Jun 28;14:1404799. doi: 10.3389/fonc.2024.1404799. eCollection 2024.
2
Development and validation of a clinical prediction model for the risk of distal metastasis in intrahepatic cholangiocarcinoma: a real-world study.开发和验证用于预测肝内胆管细胞癌远处转移风险的临床预测模型:一项真实世界研究。
BMC Gastroenterol. 2024 Jan 2;24(1):1. doi: 10.1186/s12876-023-03084-9.
3

本文引用的文献

1
Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis.肝内胆管癌:诊断和预后的分子标志物
Surg Oncol. 2017 Jun;26(2):125-137. doi: 10.1016/j.suronc.2016.12.009. Epub 2017 Feb 20.
2
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
3
International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.1978 - 2007年肝癌发病率的国际趋势,总体及按组织学亚型划分的趋势
Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database.
肝内胆管癌的发病率趋势及预后:一项基于监测、流行病学和最终结果(SEER)数据库的研究
Transl Cancer Res. 2023 Nov 30;12(11):3007-3015. doi: 10.21037/tcr-23-1278. Epub 2023 Oct 26.
4
Anatomical Resection Improved the Outcome of Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis of a Retrospective Cohort.解剖性切除改善肝内胆管癌的预后:一项回顾性队列的倾向评分匹配分析
J Oncol. 2022 Oct 25;2022:4446243. doi: 10.1155/2022/4446243. eCollection 2022.
5
Automated machine learning for differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma on multiphasic MRI.多期 MRI 肝细胞癌与肝内胆管细胞癌的自动机器学习鉴别。
Sci Rep. 2022 May 13;12(1):7924. doi: 10.1038/s41598-022-11997-w.
6
An Efficient Nomogram for Discriminating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma: A Retrospective Study.一种用于鉴别肝内胆管癌与肝细胞癌的高效列线图:一项回顾性研究
Front Oncol. 2022 Apr 11;12:833999. doi: 10.3389/fonc.2022.833999. eCollection 2022.
7
Construction and evaluation of prognostic models for esophageal cancer patients with distant and non-distant metastases: providing a reference process for clinical diagnosis and treatment.伴有远处和非远处转移的食管癌患者预后模型的构建与评估:为临床诊断和治疗提供参考流程
J Gastrointest Oncol. 2021 Aug;12(4):1241-1254. doi: 10.21037/jgo-21-429.
8
Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis.肝纤维化评分对肝内胆管癌常见治疗后预后的影响:倾向评分匹配分析。
BMC Cancer. 2020 Jun 15;20(1):556. doi: 10.1186/s12885-020-07051-5.
9
A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery.一种新的评分方法,用于预测手术治疗后合并肝细胞癌和胆管细胞癌患者的个体化预后。
J Gastrointest Surg. 2021 Apr;25(4):971-982. doi: 10.1007/s11605-020-04618-2. Epub 2020 Apr 29.
10
Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.基于炎症指标的列线图用于鉴别肝内胆管细胞癌与肝细胞癌。
Cancer Med. 2020 Feb;9(4):1451-1461. doi: 10.1002/cam4.2823. Epub 2020 Jan 5.
Int J Cancer. 2016 Oct 1;139(7):1534-45. doi: 10.1002/ijc.30211. Epub 2016 Jun 28.
4
Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma.可切除性肝门部胆管癌患者预后列线图的建立与验证
Oncotarget. 2016 Jun 14;7(24):37319-37330. doi: 10.18632/oncotarget.9104.
5
A multi-institutional analysis of elderly patients undergoing a liver resection for intrahepatic cholangiocarcinoma.一项针对接受肝内胆管癌肝切除术的老年患者的多机构分析。
J Surg Oncol. 2016 Mar;113(4):420-6. doi: 10.1002/jso.24148. Epub 2016 Jan 12.
6
Defining when to offer operative treatment for intrahepatic cholangiocarcinoma: A regret-based decision curves analysis.确定何时对肝内胆管癌进行手术治疗:基于遗憾的决策曲线分析。
Surgery. 2016 Jul;160(1):106-117. doi: 10.1016/j.surg.2016.01.023. Epub 2016 Apr 1.
7
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.《1975 - 2012年美国癌症现状年度报告》,重点关注肝癌发病率上升情况
Cancer. 2016 May 1;122(9):1312-37. doi: 10.1002/cncr.29936. Epub 2016 Mar 9.
8
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.小鼠和人类胆管癌与肝细胞癌中从头脂肪生成的差异需求
Hepatology. 2016 Jun;63(6):1900-13. doi: 10.1002/hep.28508. Epub 2016 Mar 25.
9
Nomograms for Pre-operative and Post-operative Prediction of Long-Term Survival of Patients Who Underwent Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma.复发性肝细胞癌患者再次肝切除术后长期生存的术前和术后预测列线图
Ann Surg Oncol. 2016 Aug;23(8):2618-26. doi: 10.1245/s10434-016-5136-0. Epub 2016 Feb 22.
10
Multimodality treatment of intrahepatic cholangiocarcinoma: A review.多模态治疗肝内胆管细胞癌:综述。
J Surg Oncol. 2016 Jan;113(1):62-83. doi: 10.1002/jso.24093.